Definition (if applicable) | Categorization (if applicable) | |
---|---|---|
Patient Characteristics | ||
Age | ||
Sex | ||
Race | White; African-American; Hispanic; Other | |
Comorbidities | Diabetes; HTN; CHF; CVD; COPD; Asthma; Obesity | |
Insurance | Medicare; Medicaid; Commercial; Other; Unknown | |
PCP | Name, last date of visit | |
Nephrologist | Name, last date of visit | |
Disease Characteristics | ||
CKD stage | Stages 3A, 3B, 4, 5, 5D | |
Kidney failure risk score | 2- and 5- year risk of progression to ESRDa | 2-year, 5-year risk of progression |
Rate of eGFR change | % change in eGFR by at least 90 days | |
Laboratory Data | ||
Serum creatinine | Continuous by mg/dl | |
eGFRb | Continuous by ml/min/1.73 m2 | |
Metrics | ||
ED Visits, n/per year | ||
Inpatient Visits, n/per year | ||
Outpatient PCP Visits, n/per year | ||
Outpatient Nephrology Visits, n/per year | ||
Annual creatinine | Yes or no, date obtained, value | |
Annual urine protein testing | Yes or no, date obtained, value | |
Blood pressure control | Yes, no, or unknown | |
ACE-I/ARB use | Yes, no, or not applicablec | |
Nephrotoxin status | Review of patient electronic medication list for presence of any one of several medications thought to be unsafe in patients with CKD, based on KDIGO guidelines and CKD collaborative consensus | 1. Prescribed no renally unsafe medications 2. Prescribed potentially unsafe medications 3. Prescribed renally unsafe medication (eGFR ≤30) |
Hepatitis B immunity status | 1. Immune by HbsAb 2. Immunization received 3. Not immune by HBsAb | |
Patient reported outcome measures (PROMs) | Completed, not completed, scores | |
Placement of AVF/AVGd | Yes, no | |
Transplant statuse | 1. None 2. Referral 3. Evaluation 4. Waitlist 5. Transplanted |